Study of Oxycyte in Severe Closed Head Injury
An Open Label, Proof of Concept Study, to Evaluate the Safety and Biological Effects of Oxycyte™ Perfluorocarbon in Patients With A Severe Head Injury Requiring Intracranial Pressure Monitoring-OX-CL-II-002
Sponsor: Tenax Therapeutics, Inc.
Terminated
Low enrollment
Other terminated trials from Tenax Therapeutics, Inc.
More terminations from Tenax Therapeutics, Inc.
Other Traumatic Brain Injury trials with similar outcome
Listed as NCT00174980, this PHASE2 trial focuses on Traumatic Brain Injury and remains terminated or withdrawn. Sponsored by Tenax Therapeutics, Inc., it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Sep 2024 — Feb 2026 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Sep 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tenax Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .